Product Name :
3,4-Dihydroxybenzylamine hydrobromide (CAS 16290-26-9)
Synonym :
DHBA hydrobromide
Application :
CAS:
16290-26-9
Purity:
Molecular Weight:
220.06
Formula :
C7H9NO2•Hbr
Physical state:
Solid
solubility :
Soluble in water (50 mg/ml), ethanol, oxygen-free water containing 0.1% sodium metabisulfite , and other antioxidants.
Shipping Condition :
Store at -20° C
Melting point:
184-186° C (lit.)
SMILES:
C1=CC(=C(C=C1CN)O)O.Br
References:
:High-performance liquid chromatography with electrochemical detection applied to the analysis of 3,4-dihydroxymethamphetamine in human plasma and urine. | Segura, M., et al. 2002. J Chromatogr B Analyt Technol Biomed Life Sci. 769: 313-21. PMID: 11996497Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. | Prezioso, JA., et al. 1992. J Invest Dermatol. 99: 289-93. PMID: 1512464Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells. | Prezioso, JA., et al. 1990. Pigment Cell Res. 3: 49-54. PMID: 2117268Tumor inhibition and hematological improvements by dopamine analog 3,4-dihydroxybenzylamine in mice bearing transplantable carcinoma. | Lahiri, T., et al. 1990. Neoplasma. 37: 387-93. PMID: 2234200Determination of L-3,4-dihydroxyphenylalanine in blood by high-performance liquid chromatography after solvent extraction. | Tsuchiya, H. and Hayashi, T. 1989. J Chromatogr. 491: 291-8. PMID: 2808616Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells. | Kable, EP. and Parsons, PG. 1989. Cancer Chemother Pharmacol. 23: 1-7. PMID: 2909284Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma. | FitzGerald, GB. and Wick, MM. 1987. J Invest Dermatol. 88: 66-70. PMID: 2947954Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrile.7758-89-6 supplier | Wick, MM.2923-28-6 custom synthesis and FitzGerald, GB. 1987. J Pharm Sci. 76: 513-5. PMID: 3312571Oxidative Polymerization of 3,4-DihydroxybenzylamineThe Lower Homolog of Dopamine. | Petran, A., et al. 2023. Langmuir. 39: 5610-5620. PMID: 37022985Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma. | Prakash, NJ., et al. 1985. Biochem Pharmacol. 34: 1887-90. PMID: 39240513,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymerase.PMID:33712887 | FitzGerald, GB. and Wick, MM. 1983. J Invest Dermatol. 80: 119-23. PMID: 6401786Striatal transporter for dopamine: catechol structure-activity studies and susceptibility to chemical modification. | Meiergerd, SM. and Schenk, JO. 1994. J Neurochem. 62: 998-1008. PMID: 8113819Breakdown of 3,4-dihydroxybenzylamine and dopamine in plasma of various animal species by semicarbazide-sensitive amine oxidase. | Boomsma, F., et al. 1993. J Chromatogr. 621: 82-8. PMID: 8308091Oxidation of 3,4-dihydroxybenzylamine affords 3,4-dihydroxybenzaldehyde via the quinone methide intermediate. | Sugumaran, M. 1995. Pigment Cell Res. 8: 250-4. PMID: 8789199Determination of catecholamines in sheep plasma by high-performance liquid chromatography with electrochemical detection: comparison of deoxyepinephrine and 3,4-dihydroxybenzylamine as internal standard. | He, H., et al. 1997. J Chromatogr B Biomed Sci Appl. 701: 115-9. PMID: 9389345